Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$0.62
-0.3%
$0.76
$0.47
$13.98
$1.66M0.8546,260 shs1,418 shs
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
$1.24
+0.1%
$1.05
$0.50
$10.50
$3.40M1.453.08 million shs467,261 shs
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.37
-4.4%
$3.80
$2.70
$11.68
$8.70M2.2643,685 shs13,337 shs
Neovasc Inc. stock logo
NVCN
Neovasc
$30.03
$29.69
$4.59
$30.07
$82.28M1.756,993 shs1 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
+12.73%0.00%-22.77%-26.52%-90.70%
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
-9.49%+61.67%+9.73%+15.89%-85.78%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
+5.54%+28.01%+10.12%+52.33%-60.87%
Neovasc Inc. stock logo
NVCN
Neovasc
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
2.00
HoldN/AN/A
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$250K6.65N/AN/A$2.34 per share0.26
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
$3.02M1.13N/AN/A($2.06) per share-0.60
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.47N/AN/A$13.18 per share0.33
Neovasc Inc. stock logo
NVCN
Neovasc
$3.81M21.60N/AN/A$5.77 per share5.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$9.95M-$9.01N/AN/AN/A-168.38%-122.58%5/8/2024 (Estimated)
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
-$8.03M-$12.36N/AN/A-459.42%N/A-88.87%5/20/2024 (Estimated)
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)
Neovasc Inc. stock logo
NVCN
Neovasc
-$41.20M-$15.08N/AN/A-1,082.92%-127.25%-80.31%N/A

Latest NURO, NVCN, BJDX, and INVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$0.68-$1.78-$1.10-$1.78N/AN/A
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/AN/A
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/A
1.82
1.82
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
2.94
0.15
0.12
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55
Neovasc Inc. stock logo
NVCN
Neovasc
0.80
2.96
2.85

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
18.47%
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
12.02%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%
Neovasc Inc. stock logo
NVCN
Neovasc
1.64%

Insider Ownership

CompanyInsider Ownership
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
47.00%
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
3.50%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
4.40%
Neovasc Inc. stock logo
NVCN
Neovasc
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
102.69 million1.43 millionNot Optionable
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
152.74 million2.65 millionNo Data
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.90 millionNot Optionable
Neovasc Inc. stock logo
NVCN
Neovasc
492.74 millionN/ANot Optionable

NURO, NVCN, BJDX, and INVO Headlines

SourceHeadline
Top Small-Cap Stocks for May 2023 - InvestopediaTop Small-Cap Stocks for May 2023 - Investopedia
news.google.com - May 13 at 9:38 AM
FDA accepts application for Roches Vabysmo for the - GlobeNewswireFDA accepts application for Roche's Vabysmo for the - GlobeNewswire
news.google.com - May 9 at 2:18 AM
New treatment option opens avenues in geographic atrophy - HealioNew treatment option opens avenues in geographic atrophy - Healio
news.google.com - May 8 at 9:18 PM
Pachychoroid neovasculopathy has clinical properties that differ ... - Nature.comPachychoroid neovasculopathy has clinical properties that differ ... - Nature.com
news.google.com - May 8 at 9:18 PM
The NOD audit provides data and insights for the management for ... - Modern RetinaThe NOD audit provides data and insights for the management for ... - Modern Retina
news.google.com - May 8 at 9:18 PM
Shockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswireShockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswire
news.google.com - May 8 at 4:17 PM
Heart valve repair and replacement devices market size to grow by ... - BenzingaHeart valve repair and replacement devices market size to grow by ... - Benzinga
news.google.com - May 5 at 9:03 PM
ASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry TimesASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry Times
news.google.com - May 5 at 4:02 PM
Faricimab in Treatment-Resistant nARMD | OPTH - Dove Medical PressFaricimab in Treatment-Resistant nARMD | OPTH - Dove Medical Press
news.google.com - May 5 at 12:24 AM
Restoring vision through retinal ganglion cell repopulation - Ophthalmology Times EuropeRestoring vision through retinal ganglion cell repopulation - Ophthalmology Times Europe
news.google.com - May 5 at 12:24 AM
STAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD MagazineSTAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD Magazine
news.google.com - May 4 at 7:24 PM
The NOD audit: Insights into the current state of management for ... - Nature.comThe NOD audit: Insights into the current state of management for ... - Nature.com
news.google.com - May 4 at 8:40 AM
On the horizon: Treatments for both forms of AMD - Ophthalmology Times EuropeOn the horizon: Treatments for both forms of AMD - Ophthalmology Times Europe
news.google.com - May 3 at 10:56 AM
Biosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for BiosimilarsBiosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for Biosimilars
news.google.com - April 28 at 3:22 PM
Real World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets NetworkReal World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets Network
news.google.com - April 28 at 10:22 AM
Low-vision services improve vision, quality of life in patients with ... - HealioLow-vision services improve vision, quality of life in patients with ... - Healio
news.google.com - April 28 at 10:22 AM
New Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswireNew Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswire
news.google.com - April 25 at 6:55 PM
New treatment tackles both forms of AMD - Ophthalmology TimesNew treatment tackles both forms of AMD - Ophthalmology Times
news.google.com - April 25 at 6:55 PM
Price Variation in Economic Evaluations of Infliximab Could ... - The Center for BiosimilarsPrice Variation in Economic Evaluations of Infliximab Could ... - The Center for Biosimilars
news.google.com - April 25 at 1:32 AM
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance
news.google.com - April 25 at 1:32 AM
Accel Research expands reach with acquisition of two Florida trial ... - FierceBiotechAccel Research expands reach with acquisition of two Florida trial ... - FierceBiotech
news.google.com - April 24 at 3:16 PM
Report: Boston Scientific considering massive deal to acquire ... - Cardiovascular BusinessReport: Boston Scientific considering massive deal to acquire ... - Cardiovascular Business
news.google.com - April 24 at 3:16 PM
Boston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics IndustryBoston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics Industry
news.google.com - April 21 at 4:24 PM
The Future of the Structural Heart Disease Intervention Devices ... - Digital JournalThe Future of the Structural Heart Disease Intervention Devices ... - Digital Journal
news.google.com - April 21 at 10:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bluejay Diagnostics logo

Bluejay Diagnostics

NASDAQ:BJDX
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
INVO Bioscience logo

INVO Bioscience

NASDAQ:INVO
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Neovasc logo

Neovasc

NASDAQ:NVCN
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.